STAT+: Pharmalittle: Medicare willing to reevaluate coverage of Alzheimer’s drugs; judge tosses shingles-vaccine lawsuits against Merck

Medicare is willing to reevaluate coverage of Alzheimer’s drugs in light of lecanemab, which has shown potentially more promising patient data than the controversial Aduhelm.